Results 211 to 220 of about 165,320 (303)

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting

Thrombosis Update
João Gramaça, Ana Robalo Lopes, Marta Ganhão, Joana Gonçalves, Rita Gameiro, Isabel Fernandes, Adriano Baptista, Luísa Barbosa, Idília Pina   +8 more
doaj   +1 more source

Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data

Arthritis &Rheumatology, EarlyView.
Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed, Zoe Hsu, Finlay A. McAlister, William D. Leslie, Lisa M. Lix, Sasha Bernatsky, Suzanne N. Morin, Michelle M. Graham, Aurore Fifi‐Mah, Shahin Jamal, Janet Roberts, Carrie Ye   +11 more
wiley   +1 more source

Psychiatric disorders in older adults with cancer referred to psycho-oncology service in a tertiary care cancer centre: a 7-year real world experience from India. [PDF]

BMC Psychiatry
Deodhar JK, Sonkusare LN, Goswami SS.
europepmc   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service. [PDF]

Gynecol Reprod Endocrinol, 2019
Mark J, Lynam S, Morrell K, Eng K, Starbuck K, Szender JB, Zsiros E, Frederick PJ.   +7 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source